This article by Scimega’s President Denise Deakin describes the benefits and challenges associated with personalized medicine in the clinical setting, and more specifically to the operational conduct of oncology studies – one therapeutic area that is most likely to benefit.

Click here to read how the end of one-size-fits-all medicine will effect the clinical trial industry.

What are your thoughts on this topic? Join the discussion in the Optimizing Oncology Clinical Research group on LinkedIn.